SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and upward momentum driven by intense short-squeeze dynamics, with investors closely watching a recent SEC filing regarding executive change-of-control agreements as a potential precursor to a buyout. The community is heavily focused on the scarcity of available shares, high borrow rates, and the anticipation of topline results from the Phase 3 REGAL trial for their lead AML immunotherapy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention as investors anticipate a potential inclusion in the Russell 1000, which many hope will trigger forced buying and fuel a major short squeeze against the heavily shorted float. The community remains focused on upcoming catalysts, including potential label expansions, global commercialization progress in regions like Saudi Arabia, and the company's advancements in NK cell manufacturing technology.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to a significant CFO leadership transition and the disclosure of a one-time tariff refund set to boost upcoming financial results. The community remains deeply divided, with many debating if this news marks a fundamental turnaround for the iconic brand or if the stock remains a value trap ahead of its earnings report.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors monitor the aftermath of a federal appeals court decision that affirmed the dismissal of its lawsuit against CMS, shifting focus toward the company's long-term commercial execution and revenue growth. The community remains actively focused on the potential for sustained profitability and the long-term strategic path for its flagship products as management pivots to private insurers.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors react to a new $6 billion share repurchase program, signaling management's confidence despite ongoing cyclical pressures in automotive and industrial markets. The community remains focused on the stock's potential for a long-term rebound, closely monitoring its performance as it navigates support levels and potential technical breakouts.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant strategic agreement with Fit Energy to provide up to 380 megawatts of clean, on-site power for AI data centers. The community remains sharply divided between bulls pointing to the growing proposal pipeline and data center demand, and skeptics who are raising concerns over warrant structures, potential shareholder dilution, and the opacity of the partner involved.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA has scheduled an advisory committee meeting for its DMD therapy, a development that triggered short-term volatility as traders de-risked ahead of the upcoming decision date. Despite the market's reaction, the community remains heavily focused on the company's strong five-year clinical data, viewing the meeting as a potential opportunity to secure a broader product label rather than a sign of rejection.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as retail investors engage in a heated debate over the company's lack of upward price momentum and delayed relisting plans despite aggressive store expansion and strong operational metrics. The community is actively tracking potential corporate maneuvers, including strategic buybacks and international growth efforts, while speculating on the timing of a return to major exchanges.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is experiencing a surge in interest as investors anticipate the potential impact of government-backed initiatives and index inclusion, specifically following the Russell index reconstitution news. The community is actively discussing the company's progress on its lead drug candidates and speculating on potential partnership deals, while balancing excitement over the sector's regulatory tailwinds against concerns regarding short-term price volatility.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is currently seeing intense community debate and volatility, driven by ongoing efforts to position its solid oxide fuel cell technology as a critical, on-site energy solution for power-hungry AI data centers. Investors remain sharply divided between those viewing recent pullbacks as a buying opportunity based on long-term AI infrastructure backlogs and those expressing skepticism over the stock's valuation, share dilution, and the competitive threat from other energy alternatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

🔴ICICIBANK Q2FY26 - Surprisingly super weak quarter - expect trouble on Monday.
$ICICIBANK.NSE $NIFTY50.NSE 
ICICI Bank reported mixed Q2 FY2026 results, with strong asset quality improvement leading to a significant 25.87% YoY reduction in provisions and a 5.22% YoY PAT growth. $NIFTYBANK.NSE 

However, core operating performance faced headwinds from moderating NII growth and decelerating loan and deposit momentum, alongside a sharp 12.43% YoY rise in operating expenses that exceeded guidance. 

A notable concern is the significant deterioration in H1 FY2026 operating cash flow, reversing from a strong inflow in the prior year.

💡Key Investment Insights

🟢Positive Factors

Standalone PAT grew 5.22% YoY to ₹12,358.89 crore, primarily driven by lower provisions.

Provisions saw a significant decline of 25.87% YoY and 49.62% QoQ to ₹914.11 crore, reflecting improved asset quality.

Gross NPA Ratio improved by 39 bps YoY and 9 bps QoQ to 1.58%.

Net NPA Ratio improved by 3 bps YoY and 2 bps QoQ to 0.39%.

Provisioning coverage ratio on NPAs stood at a healthy 75.0% at September 30, 2025.

The bank continues to hold a substantial contingency provision of ₹13,100 crore.

🔴Risk Factors

Net Interest Income (NII) growth moderated to 7.42% YoY and declined 0.50% QoQ, indicating pressure on margins.

Operating expenses sharply rose by 12.43% YoY, outpacing income growth and higher than the ~10% guidance.

Decelerating loan (10.27% YoY) and deposit (7.68% YoY) momentum, with sequential growth almost flat for deposits (0.27%).

Net cash flow from operating activities was a significant outflow of ₹19,166.87 crore in H1 FY2026, a sharp reversal from an inflow of ₹51,951.78 crore in H1 FY2025.

Consolidated Operating Profit Before Provisions (PPOP) was nearly flat with just 0.48% YoY growth, reflecting challenges in subsidiary businesses.

Nataraj Krishna

Bala Yogesh

Stocktwits India

Anubhav Mishra

Time to be cautious on$ICICIBANK.NSE ?🫣

@frontwave with a breakdown of its Q2 numbers 📊

$NIFTY50.NSE $NIFTYBANK.NSE

StockTwits for iOS

ICICI Bank Ltd.

🔴ICICIBANK Q2FY26 - Surprisingly super weak quarter - expect trouble on Monday.


 
ICICI Bank reported mixed Q2 FY2026 results, with strong asset quality improvement leading to a significant 25.87% YoY reduction in provisions and a 5.22% YoY PAT growth. 

 

However, core operating performance faced headwinds from moderating NII growth and decelerating loan and deposit momentum, alongside a sharp 12.43% YoY rise in operating expenses that exceeded guidance. 

A notable concern is the significant deterioration in H1 FY2026 operating cash flow, reversing from a strong inflow in the prior year.

💡Key Investment Insights

🟢Positive Factors

Standalone PAT grew 5.22% YoY to ₹12,358.89 crore, primarily driven by lower provisions.

Provisions saw a significant decline of 25.87% YoY and 49.62% QoQ to ₹914.11 crore, reflecting improved asset quality.

Gross NPA Ratio improved by 39 bps YoY and 9 bps QoQ to 1.58%.

Net NPA Ratio improved by 3 bps YoY and 2 bps QoQ to 0.39%.

Provisioning coverage ratio on NPAs stood at a healthy 75.0% at September 30, 2025.

The bank continues to hold a substantial contingency provision of ₹13,100 crore.

🔴Risk Factors

Net Interest Income (NII) growth moderated to 7.42% YoY and declined 0.50% QoQ, indicating pressure on margins.

Operating expenses sharply rose by 12.43% YoY, outpacing income growth and higher than the ~10% guidance.

Decelerating loan (10.27% YoY) and deposit (7.68% YoY) momentum, with sequential growth almost flat for deposits (0.27%).

Net cash flow from operating activities was a significant outflow of ₹19,166.87 crore in H1 FY2026, a sharp reversal from an inflow of ₹51,951.78 crore in H1 FY2025.

Consolidated Operating Profit Before Provisions (PPOP) was nearly flat with just 0.48% YoY growth, reflecting challenges in subsidiary businesses.

This account has been verified as a SEBI Research Analyst (RA).